(Reuters) - Europe's drugs regulator on Friday recommended changing some terms of the conditional approval given to antiviral drug remdesivir as a COVID-19 treatment, to make clear the conditions under which it can be used.
Doubts over remdesivir's effectiveness were raised after the World Health Organization (WHO) last month said the drug should not be used for COVID-19 patients, regardless of how ill they are, just months after Europe and the United States approved the treatment.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!